Overview
CGON market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
CGON price chart · 1M
- O
- 79.13
- H
- 80.79
- L
- 77.45
- C
- 80.79
- Vol
- 45,103.00
Daily history from Jan 25, 2024
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $79.13
- Previous Close
- $78.92
- Day High
- $80.79
- Day Low
- $77.45
- 52 Week High
- $91.94
- 52 Week Low
- $37.10
- 7 Day Return
- +11.19%
- 30 Day Return
- +34.56%
- 90 Day Return
- +4.07%
- 1 Year Return
- +89.58%
- Daily Notional Volume
- $3.6M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,851.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $37.01 – $80.97 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $7.1B · P/B 4.45 · P/S 1,143.50.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
8-K filing — CG Oncology, Inc. (CGON)SEC EDGAR ·
Wedbush Raises Price Target for CG OncologyFiscal.ai ·